Larimar Beats Q2 Loss Estimates
Larimar Therapeutics (NASDAQ:LRMR), a clinical-stage biotechnology firm focused on treatments for rare diseases such as Friedreich’s ataxia, reported its second quarter results on August 14, 2025. The key news was a net loss per share (GAAP) of $0.41 in Q2 2025, which was smaller than the expected $0.48 loss forecast by analysts. While the company reported no revenue, expenses grew due to accelerated clinical trial activities for its lead drug candidate. Management affirmed that all critical clinical and regulatory milestones remain on schedule, with a backlog of cash reserves bolstered by a recent public offering. Overall, it was a quarter marked by steady progress in drug development and strategic capital deployment.
Source: Analyst estimates for the quarter provided by FactSet.
Larimar Therapeutics develops treatments for serious rare diseases, with its primary drug candidate being nomlabofusp for Friedreich’s ataxia. This is a genetic disorder that causes nervous system damage and movement problems. Nomlabofusp is designed to increase frataxin (FXN) protein levels in cells—a key deficiency in people with the disease. The drug uses the company's Cell Penetrating Peptide (CPP) platform to deliver treatment inside patient cells, which is uncommon among existing therapies.
Source Fool.com
